Used in pharmaceutical research as a potent inhibitor of specific kinase enzymes involved in inflammatory and oncogenic signaling pathways. Shows promise in preclinical studies for targeted cancer therapy, particularly in tumors driven by overexpression of receptor tyrosine kinases. Its structure, featuring a furan carboxamide linked to a tetrazole and a substituted dihydropyrimidinone-thione core with a dibenzoannulene moiety, enables high selectivity and binding affinity, improving efficacy while reducing off-target effects. Also investigated for anti-inflammatory applications due to modulation of immune cell activity. Currently under evaluation for optimization of bioavailability and metabolic stability in drug development pipelines.